Alba Therapeutics is a biopharmaceutical company dedicated to discovering, developing and commercializing superior immunological disease and inflammation therapeutics by leveraging our barrier function technology platform delivering value to our patients, employees and shareholders. Alba's platform, the zonulin pathway, provides the ability to transiently and physiologically regulate tight junctions in cellular barriers such as the intestinal mucosa and the pulmonary epithelia. Modulation of paracellular permeability allows Alba to develop applications ranging from therapies associated with tight junction dysfunction and autoimmunity to vaccine and drug delivery.
Alba Therapeutics, Inc. is backed by a group of top tier investors including SV Life Sciences, Alta Partners and Health Cap Venture Capital.
For more information on Alba Therapeutics, Inc., please visit their web site at www.albatherapeutics.com